FSGS Case Study:
Identifying new Treatment Options For a Disease Of Interest
Delta4 identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS), a rare chronic kidney disease without any approved therapy.
Delta4 leveraged its state-of-the-art proprietary AI platform, Hyper-C, together with the expertise of its computational biologists, to generate a network-based molecular model of FSGS pathophysiology. Using this advanced computational drug screening approach, Delta4 identified clopidogrel, an anti-platelet drug, as a promising therapeutic candidate for FSGS. Clopidogrel was subsequently shown to alleviate disease progression in an accepted FSGS animal model, supporting its potential for clinical trials.
Iguratimod Case Study:
Identifying new indications for an approved compound
Delta4, a frontrunner in the TechBio realm, unveiled potential new indications for the drug Iguratimod using its AI-powered in-silico platform, Hyper-C. Tapping into sophisticated algorithms, Hyper-C meticulously analyzed the Iguratimod drug model against an extensive catalog of disease profiles, pinpointing potential avenues for indication expansion. This data potentially revolutionizes how we perceive and utilize Iguratimod in the medical field.
Dive into our video presentation to uncover the intricate processes by which Hyper-C made these revelations and explore the promising new indications. Don’t miss out on this exciting journey into the future of drug indication expansion!
Download Our Report
